Impurity Limits in Pharmaceuticals: How Specifications Are Established

Introduction

Impurity limits in pharmaceuticals are established to ensure that drug substances and finished drug products meet appropriate quality and safety requirements. During pharmaceutical manufacturing, storage, and packaging, impurities may originate from starting materials, manufacturing processes, degradation reactions, or interactions with excipients and packaging components.

Not every impurity presents the same level of risk. Some impurities may be controlled through routine manufacturing and analytical controls, while others require specific identification, toxicological assessment, or tighter limits because of their potential safety concerns.

Pharmaceutical companies establish impurity specifications by considering applicable regulatory guidelines, toxicological information, manufacturing process capability, stability data, analytical method performance, and the intended use of the medicine.

The International Council for Harmonisation (ICH) provides important guidance in this area. ICH Q3A(R2) addresses impurities in new drug substances, ICH Q3B(R2) addresses degradation products in new drug products, and ICH M7(R2) addresses DNA-reactive mutagenic impurities.

This article explains the main types of pharmaceutical impurities, the difference between impurity thresholds and specification limits, and how manufacturers establish and justify appropriate acceptance criteria.

What Are Impurities in Pharmaceuticals?

An impurity is an unwanted component present in a drug substance or drug product that is not the intended active pharmaceutical ingredient or an authorized formulation component.

Impurities can arise during synthesis, formulation, manufacturing, storage, or contact with packaging materials. Their presence must be assessed according to their identity, concentration, potential impact on safety, and applicable quality requirements.

For example, an active pharmaceutical ingredient (API) may develop a degradation product during storage. A finished tablet may also contain residual solvents from manufacturing or trace amounts of an impurity carried over from a starting material.

The presence of an impurity does not automatically mean that a product is unsafe. Its significance depends on its properties, level, exposure, and the relevant regulatory requirements.

Types of Pharmaceutical Impurities

1. Organic Impurities

Organic impurities are carbon-containing substances that may originate from the synthesis, processing, or degradation of a drug substance or product.

Examples include:

• Starting materials and intermediates.
• Reaction by-products.
• Reagents or related process impurities.
• Degradation products.
• Isomeric impurities, where relevant.

These impurities are commonly evaluated using suitable analytical techniques, such as high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), or gas chromatography (GC), depending on their properties.

2. Inorganic Impurities

Inorganic impurities may arise from manufacturing reagents, catalysts, processing aids, equipment, or other sources.

Examples include:

• Inorganic salts.
• Residual catalysts.
• Certain elemental impurities.
• Inorganic reagents and process-related residues.

The appropriate assessment and control strategy depends on the type of impurity and applicable guidance. Elemental impurities, for example, are addressed through the relevant risk-based framework, including ICH Q3D where applicable.

3. Residual Solvents

Residual solvents are organic volatile chemicals used or generated during manufacturing and that may remain in the drug substance or product.

ICH Q3C provides guidance on residual solvent classification and control. The acceptable level depends on the solvent’s toxicological classification, permitted daily exposure, and applicable requirements.

4. Degradation Products

Degradation products form when a drug substance or product undergoes chemical or physical changes.

Potential causes include:

• Exposure to heat or light.
• Oxidation.
• Hydrolysis.
• Changes in pH.
• Interactions with excipients.
• Interactions with packaging components.

Stability studies help identify degradation patterns and determine whether degradation products remain within established acceptance criteria throughout the proposed shelf life.

5. Mutagenic Impurities

Certain impurities may have the potential to cause genetic mutations and require a specific assessment strategy.

ICH M7(R2) addresses the assessment and control of DNA-reactive mutagenic impurities to limit potential carcinogenic risk. These impurities should not automatically be assessed using the same thresholds applied to ordinary organic impurities.

What Are Impurity Limits?

An impurity limit is an established acceptance criterion used to determine whether the amount of a specified or unspecified impurity is acceptable for the intended purpose of a drug substance or product.

Limits may be expressed as:

• A percentage relative to the drug substance or active ingredient.
• A concentration, such as parts per million (ppm).
• An amount per unit dose.
• A maximum daily intake.
• Another scientifically justified measure appropriate to the impurity and applicable requirement.

The correct expression depends on the impurity, analytical procedure, product, and governing guideline.

An impurity specification is more than a numerical value. It should identify the relevant impurity or impurity category, define the acceptance criterion, and reference a suitable analytical procedure where required.

Impurity Threshold vs Specification Limit

These terms are related but are not interchangeable.

A reporting, identification, or qualification threshold is not automatically the final specification limit.

For example, an impurity may be detected above a reporting threshold but still be acceptable if it is identified, appropriately assessed, and within its justified specification limit. Conversely, a potentially hazardous impurity may require a tighter control strategy even when its concentration is low.

The applicable guideline, impurity identity, safety information, and product-specific context determine the appropriate action.

Which ICH Guidelines Are Used to Establish Impurity Limits?

ICH Q3A(R2): Impurities in New Drug Substances

ICH Q3A(R2) addresses impurities in new drug substances produced by chemical synthesis that fall within its scope.

It provides principles for reporting, identifying, qualifying, and controlling organic impurities. It also addresses the inclusion of specified and unspecified impurities and total impurity limits in drug substance specifications, where applicable.

The relevant thresholds depend on factors including the maximum daily dose. Impurity limits must also be supported by safety considerations and manufacturing and analytical data.

Official reference: https://www.ema.europa.eu/en/scientific-guidelines/ich-q3a-r2-impurities-new-drug-substances

ICH Q3B(R2): Impurities in New Drug Products

ICH Q3B(R2) addresses degradation products in new drug products containing chemically synthesized drug substances within its scope.

It considers degradation products arising during manufacture and storage, including those potentially formed through interactions with excipients or primary packaging materials.

The guideline provides principles for reporting, identification, qualification, and control of degradation products. Its thresholds differ from those in Q3A and depend on the applicable factors, including maximum daily dose.

Official reference: https://www.ema.europa.eu/en/scientific-guidelines/ich-q3b-r2-impurities-new-drug-products

ICH Q3C: Impurities—Guideline for Residual Solvents

ICH Q3C provides a framework for controlling residual solvents based on their toxicological assessment and permitted daily exposure.

The appropriate control limit depends on the solvent, the product’s maximum daily dose, the applicable option or calculation approach, and relevant regulatory requirements.

ICH Q3D: Elemental Impurities

ICH Q3D provides a risk-based framework for evaluating and controlling elemental impurities in drug products.

The assessment considers potential sources, route of administration, daily exposure, and applicable permitted daily exposure limits. It should not be treated as a generic percentage-based organic impurity framework.

ICH M7(R2): Mutagenic Impurities

ICH M7(R2) provides guidance for assessing and controlling DNA-reactive mutagenic impurities to limit potential carcinogenic risk.

The assessment considers the impurity’s mutagenic potential, intended duration of treatment, patient exposure, and other relevant factors. Compound-specific acceptable intakes or other justified approaches may be necessary.

Official reference: https://www.ema.europa.eu/en/scientific-guidelines/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk

Important: These guidelines have different scopes. The correct guideline must be selected before determining the applicable impurity thresholds or specification limits.

How Are Impurity Limits Established in Pharma?

Step 1: Identify Potential Impurities

The manufacturer first identifies potential impurities based on the chemistry and manufacturing process of the drug substance or product.

Sources may include:

• Starting materials and intermediates.
• Reagents, catalysts, and solvents.
• Reaction by-products.
• Degradation during manufacture or storage.
• Excipient or packaging interactions.
• Equipment or processing-related sources, where relevant.

Process knowledge, development studies, analytical testing, and risk assessments help establish the potential impurity profile.

Step 2: Determine the Applicable Regulatory Framework

The impurity should be classified according to its nature and source.

For example, a process-related organic impurity in a chemically synthesized drug substance may fall within the scope of ICH Q3A. A degradation product in a finished product may fall within Q3B, while residual solvents, elemental impurities, and mutagenic impurities require their relevant control frameworks.

This classification is important because the thresholds, calculations, and safety considerations are not identical across these guidelines.

Step 3: Establish the Relevant Thresholds

Determine the reporting, identification, and qualification thresholds specified by the applicable guideline.

Factors may include:

• Maximum daily dose.
• Impurity type and identity.
• Potential toxicity.
• Intended route and duration of administration, where relevant.
• Existing safety and clinical information.
• Guideline-specific provisions and exceptions.

Thresholds should be taken from the current applicable guideline rather than copied from a general impurity table without checking the scope.

Step 4: Evaluate Analytical Data

The manufacturer assesses analytical results from appropriate batches, development studies, and stability studies.

The evaluation may include:

• Individual impurity levels.
• Total impurity levels.
• Batch-to-batch variability.
• Changes during storage.
• Analytical method sensitivity and specificity.
• The ability of the method to quantify impurities reliably at the proposed limit.

The analytical procedure must be suitable for the intended measurement. A specification limit cannot be supported adequately if the analytical method is unable to measure the impurity with suitable performance.

Step 5: Assess Safety and Qualification

The safety assessment determines whether the impurity level is adequately supported by relevant toxicological, clinical, or other scientific evidence.

Where the applicable threshold is exceeded, additional identification or qualification may be necessary unless an appropriate justification or exception applies.

An impurity that has been adequately assessed at a given exposure may be considered qualified at that level. However, the existence of some safety data does not automatically justify any higher proposed limit.

Step 6: Review Manufacturing and Stability Trends

The proposed specification should reflect relevant batch data, process understanding, analytical capability, and stability characteristics.

Consistently low impurity levels may indicate effective process control. Significant or unexplained variation between batches may indicate a manufacturing issue requiring investigation.

For drug products, stability studies help establish whether degradation products increase during storage and whether the proposed limits remain appropriate throughout the shelf life.

Step 7: Establish the Proposed Specification

The proposed impurity specification should be justified by the applicable guideline, safety considerations, process capability, analytical performance, and relevant product data.

Depending on the case, specifications may include:

• Limits for specified identified impurities.
• Limits for specified unidentified impurities, where justified.
• A limit for any unspecified impurity.
• A total impurity limit.
• Separate controls for residual solvents, elemental impurities, or mutagenic impurities where applicable.

The exact specification should reflect the product’s needs and applicable regulatory commitments.

Step 8: Document and Approve the Limits

The rationale for each proposed limit should be documented in the relevant quality and regulatory records.

Supporting evidence may include analytical results, batch data, stability studies, toxicological assessments, method validation information, and regulatory justifications.

The specification and associated methods should be reviewed and approved through the applicable quality system.

Worked Example: Establishing a Limit for an Organic Impurity

Consider a fictional chemically synthesized drug substance with a potential organic process impurity.

During development, the manufacturer identifies the impurity, evaluates its safety information, reviews the relevant ICH Q3A(R2) thresholds, and assesses analytical results from representative batches.

Assume the following illustrative data:

The proposed 0.10% limit is an illustrative value only. It is not a universal or automatically acceptable regulatory limit.

To justify this specification, the manufacturer would need to demonstrate that the impurity is appropriately identified or otherwise addressed under the applicable guideline, that the proposed level is adequately supported by safety information, and that the limit is consistent with the relevant process, analytical, and stability data.

If the impurity presents a specific safety concern, a tighter limit may be necessary even if the process routinely produces levels below 0.10%.

If the impurity level increases unexpectedly during manufacture or storage, the manufacturer should investigate the change rather than relying only on the fact that the result remains below the specification.

How Are Impurity Limits Calculated?

The calculation depends on the applicable impurity guideline and the basis on which the result is expressed.

For a simple percentage-based result:

Impurity percentage = (Amount of impurity ÷ Relevant reference amount) × 100

For example, if an impurity amount is 0.8 mg and the relevant reference amount is 1,000 mg:

Impurity percentage = (0.8 ÷ 1,000) × 100 = 0.08%

This arithmetic example assumes that both quantities use a consistent basis and that the analytical result supports the calculation. Actual pharmaceutical reporting may require response-factor corrections, specific reference standards, or other method-defined calculations.

For certain impurity assessments, exposure may be expressed as an amount per day:

Daily impurity intake = Impurity concentration × Daily amount of drug administered

The units must be consistent. For example, a concentration expressed in mg/kg must be converted appropriately before calculating an intake in mg/day.

For mutagenic impurities or other specifically controlled impurities, the applicable calculation and acceptable intake must follow the relevant guideline and scientific justification.

What Happens When an Impurity Exceeds Its Limit?

An impurity result above an established specification should be handled under the applicable laboratory and quality procedures.

The response may include:

1. Verification of the result and review of the original analytical data.
2. Assessment of analytical system suitability and method performance.
3. Investigation of possible laboratory, manufacturing, or degradation-related causes.
4. Evaluation of the impurity’s identity, source, and potential safety impact.
5. Assessment of affected batches and relevant stability data.
6. Documentation of the investigation, conclusions, and corrective actions where required.
7. Appropriate disposition and regulatory assessment according to the applicable quality system.

A result above specification should not be dismissed simply because the impurity is chemically familiar or has been observed in earlier batches. Likewise, repeat testing should not be used to replace a scientifically justified investigation.

Common Mistakes When Establishing Impurity Specifications

1. Treating All Thresholds as Specification Limits

Reporting, identification, and qualification thresholds serve different purposes and do not automatically determine the final specification.

Good practice: Document the rationale for the proposed limit separately from the threshold assessment.

2. Applying the Wrong ICH Guideline

Drug substance impurities, drug product degradation products, residual solvents, elemental impurities, and mutagenic impurities have different control frameworks.

Good practice: Establish the impurity’s category and applicable guideline before setting the limit.

3. Ignoring Maximum Daily Dose

Some guideline thresholds depend on the maximum daily dose. Using the wrong dose category can lead to an incorrect threshold assessment.

Good practice: Verify the relevant dose and units against the applicable guideline.

4. Setting Limits Only From Historical Batch Data

Historical process capability is important, but it does not independently establish that an impurity level is safe.

Good practice: Consider safety, applicable thresholds, process capability, analytical performance, and stability together.

5. Overlooking Degradation During Shelf Life

An impurity level acceptable at release may increase during storage.

Good practice: Review relevant stability data and justify the specification over the intended shelf life.

6. Using an Unsuitable Analytical Method

A method with inadequate sensitivity, specificity, or quantitation performance may not reliably assess an impurity near its limit.

Good practice: Demonstrate that the method is suitable for the impurity and intended reporting level.

FAQs

1. What determines impurity limits in pharmaceuticals?

Impurity limits are established using the applicable regulatory framework, impurity identity and type, safety information, maximum daily dose where relevant, manufacturing data, analytical method performance, and stability results.

2. Are reporting and identification thresholds the same?

No. The reporting threshold concerns when results should generally be reported, while the identification threshold concerns when identification may be required. Both are distinct from the qualification threshold and the final specification limit.

3. What is the difference between ICH Q3A and ICH Q3B?

ICH Q3A(R2) addresses impurities in new drug substances within its scope. ICH Q3B(R2) addresses degradation products in new drug products containing chemically synthesized drug substances within its scope.

4. Does every impurity require a separate specification?

Not necessarily. The appropriate controls depend on the impurity, applicable guideline, and product. Some impurities may require individual limits, while other controls may apply to unspecified or total impurities or to separate impurity categories.

5. Can a specification limit be higher than the observed batch levels?

A proposed limit may be higher than typical observed levels if the difference is scientifically justified and the limit meets applicable safety and regulatory requirements. It should also be consistent with process capability, analytical performance, and stability data.

6. Are mutagenic impurities controlled using the same thresholds as ordinary organic impurities?

Not necessarily. Mutagenic impurities require assessment under the applicable framework, such as ICH M7(R2), which considers potential carcinogenic risk and appropriate acceptable intakes or control strategies.

7. Why are stability studies important for impurity limits?

Stability studies help determine whether impurities form or increase over time. The results support assessment of the impurity profile and the suitability of specifications throughout the proposed shelf life.

Conclusion

Impurity limits in pharmaceuticals are established through a combination of regulatory guidance, scientific assessment, analytical data, safety information, manufacturing knowledge, and stability studies.

The key is to distinguish the different impurity categories and understand that reporting, identification, and qualification thresholds are not interchangeable with final specification limits.

By applying the appropriate ICH framework and documenting a clear scientific rationale, pharmaceutical manufacturers can establish impurity specifications that support product quality, patient safety, and regulatory compliance.

References

1. International Council for Harmonisation (ICH). Q3A(R2): Impurities in New Drug Substances.
   https://www.ema.europa.eu/en/scientific-guidelines/ich-q3a-r2-impurities-new-drug-substances
2. International Council for Harmonisation (ICH). Q3B(R2): Impurities in New Drug Products.
   https://www.ema.europa.eu/en/scientific-guidelines/ich-q3b-r2-impurities-new-drug-products
3. International Council for Harmonisation (ICH). Q3C: Impurities—Guideline for Residual Solvents.
   https://www.ich.org/page/quality-guidelines
4. International Council for Harmonisation (ICH). Q3D: Guideline for Elemental Impurities.
   https://www.ich.org/page/quality-guidelines
5. International Council for Harmonisation (ICH). M7(R2): Assessment and Control of DNA-Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk.
   https://www.ema.europa.eu/en/scientific-guidelines/ich-m7-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk
6. U.S. Food and Drug Administration (FDA). Q6A: Specifications—Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.
   https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products